Subscribe here to receive future editions. AstraZeneca said it is doubling down on its investment in its U.S. business, a ...

AstraZeneca Plc (NASDAQ: AZN) Q3 2024 Earnings Call Nov 12, 2024, 9:00 a.m. ET ...

AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...

Four years after winning an FDA approval for Koselugo to treat children with the rare disorder neurofibromatosis type 1 (NF1) ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

Full Year Guidance Upgrade (2024): Total revenue and core EPS expected to grow by high 10s percentage. AstraZeneca PLC ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

AstraZeneca Pharma India on Wednesday said its net profit declined by 27 per cent on-year to Rs 38 crore in the second ...

Eric Le Berrigaud, an analyst from Stifel Nicolaus, reiterated the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with p14,100.00. Eric Le Berrigaud ...

Profit after tax came in ₹38.4 crore in Q2 of FY25, a recovery from a net loss of ₹11.8 crore in the first quarter of this ...

AstraZeneca boss Pascal Soriot (pictured)) threw his weight behind its Chinese business despite the recent arrest of its boss ...

Recent health news highlights include Amgen addressing bone density concerns, AstraZeneca revising its financial outlook ...